SCM
HRTX icon

Stonepine Capital Management’s Heron Therapeutics HRTX Stock Holding History

Stonepine Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$800K Buy
+1,000,000
New +$1.16M 0.32% 45

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Stonepine Capital Management's HRTX Position: Q1 2026 in Review

Stonepine Capital Management increased its Heron Therapeutics (HRTX) stake by 13% in Q1 2026, buying an estimated $190K and bringing the position to 1,402,191 shares worth $1.12M. The position accounts for 0.45% of the portfolio, ranked #33.

Stonepine Capital Management first reported a position in HRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.75M in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Stonepine Capital Management held 1,402,191 shares of Heron Therapeutics worth $1.12M as of Q1 2026.
  • Stonepine Capital Management bought 164,389 Heron Therapeutics shares in Q1 2026, an estimated $190K.
  • Heron Therapeutics made up 0.45% of Stonepine Capital Management's portfolio in Q1 2026, its #33 holding.
  • Stonepine Capital Management first reported a position in Heron Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Stonepine Capital Management's Heron Therapeutics position peaked at $1.75M in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.